Published in Helicobacter on December 01, 2000
H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut (2004) 4.66
New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol (2008) 2.83
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol (2008) 1.52
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol (2017) 1.11
Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother (2003) 0.99
A meta-analysis of the success rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol (2007) 0.98
A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. Can J Gastroenterol (2013) 0.92
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am (2015) 0.87
Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol (2014) 0.86
Facing resistance of H.pylori infection. Gastroenterol Hepatol Bed Bench (2011) 0.80
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther (2002) 6.17
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology (1997) 4.59
Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model. J Clin Microbiol (1997) 3.57
Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. Gut (1983) 3.46
Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology (1999) 3.37
Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst (1997) 3.30
Macrolide resistance in Helicobacter pylori: rapid detection of point mutations and assays of macrolide binding to ribosomes. Antimicrob Agents Chemother (1997) 3.27
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter (1996) 3.13
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology (1999) 2.64
Susceptibility of Campylobacter pyloridis to 20 antimicrobial agents. Antimicrob Agents Chemother (1986) 2.26
Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol (2005) 2.20
Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2009) 2.11
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis (2001) 2.10
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother (1999) 2.07
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol (1997) 2.02
Magnetic resonance imaging pelvimetry: a useful adjunct in the management of the obese patient. Br J Obstet Gynaecol (1992) 2.02
Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. J Clin Microbiol (1998) 2.02
Effect of inositol-1,4,5-trisphosphate on isolated subcellular fractions of rat pancreas. J Membr Biol (1984) 2.00
In vitro model for Campylobacter pylori adherence properties. Infect Immun (1988) 1.97
Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc (2000) 1.94
Metabolism and genetics of Helicobacter pylori: the genome era. Microbiol Mol Biol Rev (1999) 1.92
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther (2003) 1.91
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol (1997) 1.81
Rifampin and rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother (1999) 1.80
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther (1999) 1.80
Gastric carcinoma risk index in patients infected with Helicobacter pylori. Virchows Arch (1998) 1.79
Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther (2011) 1.76
Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology (2000) 1.76
Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther (2003) 1.76
Matrix-assisted laser-desorption/ionization biotyper: experience in the routine of a University hospital. Clin Microbiol Infect (2011) 1.74
Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol (1999) 1.74
Measuring quality of life in clinical trials: a taxonomy and review. CMAJ (1989) 1.73
Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin, and growth hormone in normal, diabetic, acromegalic, and hypopituitary patients. Lancet (1974) 1.71
Distribution of open reading frames of plasticity region of strain J99 in Helicobacter pylori strains isolated from gastric carcinoma and gastritis patients in Costa Rica. Infect Immun (2000) 1.67
Helicobacter and gastric MALT lymphoma. Gut (2002) 1.66
Effects of substituted benzimidazole (H 149/94) on gastric acid secretion in humans. Gastroenterology (1982) 1.66
Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol (2002) 1.66
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther (2004) 1.64
Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut (1997) 1.64
Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet (1982) 1.63
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother (2001) 1.60
Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis (2006) 1.57
GC content of DNA of Campylobacter pylori and other species belonging or related to the genus Campylobacter. Ann Inst Pasteur Microbiol (1989) 1.54
The epidemiology of shoulder dislocations. Arch Orthop Trauma Surg (1989) 1.53
Maternal body mass index in early pregnancy and offspring asthma, rhinitis and eczema up to 16 years of age. Clin Exp Allergy (2015) 1.53
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther (2003) 1.52
Impact of reflux disease on general and disease-related quality of life - evidence from a recent comparative methodological study in Germany. Z Gastroenterol (2003) 1.52
A comparison of Helicobacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients. Scand J Gastroenterol (1997) 1.51
Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther (2015) 1.51
Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population--the Kalixanda study. Aliment Pharmacol Ther (2006) 1.49
Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res (1996) 1.49
Laboratory-acquired Helicobacter pylori infection. Lancet (1995) 1.49
Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol (2004) 1.47
Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol (2001) 1.47
Antenatal screening for diabetes mellitus. Br J Obstet Gynaecol (1984) 1.47
The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer (2000) 1.46
[Comparison of quantifying Helicobacter pylori gastric infection by culture, histology and C13 urea breath test]. Gastroenterol Clin Biol (1998) 1.46
[Helicobacter pylori and stomach carcinoma. Is a preventive intervention study of value?]. Pathologe (1998) 1.45
Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer (2000) 1.44
Development of a real-time fluorescence resonance energy transfer PCR to identify the main pathogenic Campylobacter spp. Clin Microbiol Infect (2005) 1.43
Haemophilus species in the human gastrointestinal tract. Eur J Clin Microbiol Infect Dis (1988) 1.42
Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol (1995) 1.42
[CagA status and virulence of Helicobacter pylori strains. Results of a French multicentric prospective study]. Gastroenterol Clin Biol (2001) 1.42
The EXT1/EXT2 tumor suppressors: catalytic activities and role in heparan sulfate biosynthesis. EMBO Rep (2000) 1.41
A serial study of changes occurring in the oral glucose tolerance test during pregnancy. J Obstet Gynaecol Br Commonw (1973) 1.41
Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. Allergy (2012) 1.41
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther (2003) 1.40
[Dysphagia revealing Crohn's disease]. Gastroenterol Clin Biol (1998) 1.38
Adjusting outcome measurements for case-mix in a vascular surgical register--is it possible and desirable? Eur J Vasc Endovasc Surg (1996) 1.38
Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. N Engl J Med (1984) 1.36
Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol (1997) 1.36
Fetal heart rate monitoring during labour--too frequent intervention, too little benefit? Lancet (1987) 1.36
Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol (2001) 1.35
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol (2001) 1.34
Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut (2005) 1.34
Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori. Antimicrob Agents Chemother (2000) 1.31
Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother (1999) 1.30
Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer (2003) 1.30
Gastric MALT lymphoma and its relationship to Helicobacter pylori infection: management and pathogenesis of the disease. Microsc Res Tech (2000) 1.29
Development of early gastric cancer 4 and 5 years after complete remission of Helicobacter pylori associated gastric low grade marginal zone B cell lymphoma of MALT type. World J Gastroenterol (2001) 1.28
Red cell mass during and after normal pregnancy. Br J Obstet Gynaecol (1979) 1.28
Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol (2000) 1.26
Changes in serum uric acid concentrations during normal pregnancy. Br J Obstet Gynaecol (1984) 1.26
Susceptibility of Campylobacter jejuni and Campylobacter coli to macrolides and related compounds. Antimicrob Agents Chemother (1985) 1.25
Detection of Helicobacter pylori DNA in human feces by PCR: DNA stability and removal of inhibitors. J Microbiol Methods (2001) 1.25
In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother (2001) 1.24
Pattern of adhesion molecule expression on vascular endothelium in Helicobacter pylori-associated antral gastritis. Gastroenterology (1997) 1.22
Isolation of Campylobacter species by filtration. Eur J Clin Microbiol (1985) 1.22
Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut (2006) 1.20